You are here: Industry Insights > Tagrisso

News List

Tagrisso shows 'unprecedented' disease free survival in lung cancer pharmatimes
June 01, 2020
According to AstraZeneca, its EGFR inhibitor Tagrisso (osimertinib) has shown 'unprecedented disease-free survival' in the adjuvant treatment of patients with EGFR-mutated lung cancer.
China grants Tagrisso (osimertinib) marketing authorisation europeanpharmaceuticalreview
September 06, 2019
Following positive clinical trials, the Tagrisso drug has been given marketing authorisation in China for treatment of NSCLC.
Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer worldpharmanews
September 05, 2019
AstraZeneca announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-line treatment for adults with locally-advanced...
AstraZeneca demonstrates Tagrisso’s superiority to other EGFR-TKI drugs pharmaceutical-technology
August 12, 2019
AstraZeneca has published results from its Phase III FLAURA trial showing that in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) its drug Tagrisso (osimertinib) performed better than erlotinib or ...
TAGRISSO Shows Improved Overall Survival in Trial for NSCLC americanpharmaceuticalreview
August 12, 2019
AstraZeneca announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomized, double-blinded, multicenter trial of TAGRISSO in previously-untreated patients with locally-advanced or ...
NICE shuts down AZ's Tagrisso—and backs Pfizer rival Vizimpro instead fiercepharma
July 09, 2019
England’s cost watchdogs won’t get behind AstraZeneca blockbuster Tagrisso in previously untreated patients with EGFR-mutated lung cancer. But in a change of events, they’re instead backing a Pfizer challenger.
AZ’ Tagrisso offers sustained benefit in lung cancer pharmatimes
July 17, 2018
AstraZeneca says that the “unprecedented progression-free survival benefit” of Tagrisso when used as a first line treatment for lung cancer is sustained through subsequent lines of therapy.
Forget Tagrisso's $3B sales target. It'll be worth double that by 2023, analyst says fiercepharma
June 26, 2018
Recent approvals of Tagrisso in the first-line lung cancer setting have AstraZeneca management optimistic about the $3 billion sales target it set several years ago. But some analysts have higher hopes—and one just came up with a bullish estimate that's o
AstraZeneca receives EU nod for lung cancer drug Tagrisso biospectrumasia
June 13, 2018
Tagrisso is a monotherapy for the 1st-line treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer
AZ’s Tagrisso brings ‘unprecedented’ benefit in untreated NSCLC pharmaphorum
April 18, 2018
AstraZeneca says its lung cancer drug Tagrisso has produced “unprecedented” survival benefit from first-line use in some patients with advanced disease.

Previous page 1 2 3 4 Next page